重症疾病对侵袭性血液恶性肿瘤患者抗肿瘤治疗延续及预后的影响
该单中心回顾性观察研究纳入2013-2021年ICU非计划入住后存活出院的AML(n=92)和B-NHL(n=78)患者共170例,评估ICU出院后抗肿瘤治疗方案的改变及1年无进展生存和总生存。结果显示42%患者需修改血液肿瘤治疗方案,58%能恢复原定方案;年龄>65岁(OR 3.54)、ICU出院时高胆红素血症>20 µmol/L(OR 3.01)和治疗限制决策(OR 16.5)是方案修改的独立决定因素。ICU出院后1年生存率为59.5%,方案修改与院内、1年总生存和无进展生存显著相关。
要点
- 170例ICU存活出院的AML或B-NHL患者中,42%(72例)需修改原定血液肿瘤治疗方案,58%能恢复原定方案。
- 年龄>65岁(OR 3.54,95%CI 1.67-7.50,p<0.001)是ICU出院后修改抗肿瘤方案的独立决定因素。
- ICU出院时高胆红素血症>20 µmol/L(OR 3.01,95%CI 1.10-8.15,p=0.031)独立关联方案修改。
- 治疗限制决策(OR 16.5,95%CI 1.83-149.7,p=0.012)与方案修改独立相关。
- ICU出院后1年生存率59.5%,方案修改与院内、1年总生存及无进展生存显著相关。
适用人群与场景
- 2013-2021年单中心ICU非计划入住后存活出院的成人AML或侵袭性B-NHL患者(n=170,AML 92例、B-NHL 78例)。
- 68%患者血液恶性肿瘤为近期诊断;入ICU时SOFA评分中位数5(四分位距4-8)。
研究设计与关键结果
- 研究类型:2013-2021年单中心回顾性观察研究;纳入ICU非计划入住后存活出院的AML或B-NHL患者170例(AML n=92,B-NHL n=78)。
- ICU期间30例(17.6%)需有创机械通气,29例(17.0%)需血管活性药物支持,16例(9.4%)需肾脏替代治疗。
- 主要终点:ICU出院后需修改血液肿瘤治疗方案者72例(42%),即58%能恢复原定方案。
- 多因素分析:年龄>65岁(OR 3.54,95%CI 1.67-7.50,p<0.001)、ICU出院时高胆红素血症>20 µmol/L(OR 3.01,95%CI 1.10-8.15,p=0.031)、治疗限制决策(OR 16.5,95%CI 1.83-149.7,p=0.012)独立关联治疗方案修改。
- ICU出院后1年生存率59.5%;ICU出院后治疗方案修改对院内生存、1年总生存和无进展生存有显著影响。
证据类型、等级与局限
- 证据类型:单中心回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对ICU存活出院的侵袭性血液恶性肿瘤患者,出ICU时应评估年龄、胆红素及治疗限制决策,以识别抗肿瘤方案可能需要修改的高危患者。
- 原文结论提示ICU出院后治疗方案修改与1年预后恶化相关,但未据此给出具体推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Maintaining the dose-intensity of cancer treatment is an important prognostic factor of aggressive hematological malignancies. The objective of this study was to assess the long-term outcomes of intensive care unit (ICU) survivors with acute myeloid leukemia (AML) or aggressive B-cell non-Hodgkin lymphoma (B-NHL) with emphasis on the resumption of the intended optimal regimen of cancer treatment.
PATIENTS AND METHODS: We conducted a retrospective (2013-2021) single-center observational study where we included patients with AML and B-NHL discharged alive from the ICU after an unplanned admission. The primary endpoint was the change in the intended optimal cancer treatment following ICU discharge. Secondary endpoints were 1-year progression-free survival and overall survival rates. Determinants associated with modifications in cancer treatment were assessed through multivariate logistic regression.
RESULTS: Over the study period, 366 patients with AML or B-NHL were admitted to the ICU, of whom 170 survivors with AML (n = 92) and B-NHL (n = 78) formed the cohort of interest. The hematological malignancy was recently diagnosed in 68% of patients. The admission Sequential Organ Failure Assessment (SOFA) score was 5 (interquartile range 4-8). During the ICU stay, 30 patients (17.6%) required invasive mechanical ventilation, 29 (17.0%) vasopressor support, and 16 (9.4%) renal replacement therapy. The one-year survival rate following ICU discharge was 59.5%. Further modifications in hematologic treatment regimens were required in 72 patients (42%). In multivariate analysis, age > 65 years (odds ratio (OR) 3.54 [95%-confidence interval 1.67-7.50], p < 0.001), ICU-discharge hyperbilirubinemia > 20 µmol/L (OR 3.01 [1.10-8.15], p = 0.031), and therapeutic limitations (OR 16.5 [1.83-149.7], p = 0.012) were independently associated with modifications in cancer treatment. Post-ICU modifications of cancer treatment had significant impact on in-hospital, 1-year overall survival and progression-free survival.
CONCLUSION: The intended cancer treatment could be resumed in 58% of ICU survivors with aggressive hematological malignancies. At the time of ICU discharge, advanced age, persistent liver dysfunction and decisions to limit further life-support therapies were independent determinants of cancer treatment modifications. These modifications were associated with worsened one-year outcomes.
参考来源
- Bredin S, Decroocq J, Devautour C, et al. Impact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies. Ann Intensive Care. 2024. PMID: 39259434. doi:10.1186/s13613-024-01372-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。